Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cognex Launches New Version of Identification and Label Verification Software

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
In-Sight Track & Trace enables pharmaceutical serialization.

Cognex Corporation  announced a new version of the In-Sight® Track & Trace identification and data verification solution for healthcare serialization.

A follow up to successful deployments of In-Sight Track & Trace 1.0, this version includes enhancements that address additional requirements for pharmaceutical and medical device manufacturers to achieve unit-level product traceability.

Customers can use In-Sight Track & Trace 2.0 with multiple networked In-Sight vision systems to decode human-readable text along with 2-D and 1-D barcodes, including Data Matrix, GS1-128, GS1 DataBar, securPharm and Pharmacode.

“In-Sight Track & Trace is an off-the-shelf label verification and serialization software supplement for our pharmaceutical customers required to comply with GS1 and FDA regulations and similar laws worldwide,” says Herbert Lade, Vice President and Business Unit Manager, Vision Systems. He adds, “In the newest version, we incorporated bundling reading support, secondary authentication capability and our OCRMax™ tool for the highest read rates in the industry. This new feature provides superior read rates of human-readable dates, lot codes and serial numbers.”

The pre-programmed add-on software package needs little set up through a touch screen or HMI. In-Sight Track & Trace can be easily integrated into third-party serialization software or MES with industrial protocol support and built-in I/O controls. The technical controls needed for FDA 21 CFR Part 11 validation, including secure user authentication and automatic audit trail generation, are also included.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
NIH Launches Early-Stage Yellow Fever Vaccine Trial
Researchers at NIH have begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!